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Preoperative neutrophil-to-lymphocyte ratio
is an independent prognostic marker in patients
with laryngeal squamous cell carcinoma
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Abstract
Background: Neutrophil-lymphocyte ratio (NLR) has been shown to be associated with prognosis in various solid
tumors. This study aimed to evaluate the prognostic role of NLR in patients with laryngeal squamous cell carcinoma
(LSCC).
Methods: A total of 141 LSCC patients were retrospectively reviewed. Patients’ demographics were analyzed along
with clinical and pathologic data. The optimal cutoff value of NLR was determined using receiver operating
characteristic (ROC) curve analysis. The impact of the NLR and other potential prognostic factors on disease-free
survival (DFS) and overall survival (OS) was assessed using the Kaplan-Meier method and multivariate Cox regression
analysis.
Results: The optimal cutoff value of the NLR was 2.17. In the NLR ≤ 2.17 group, the 1-, 3-, and 5-year DFS rates
were 88.2, 73.9 and 69.1 %, respectively, while in the NLR > 2.17 group, the DFS rates were 83.0, 54.6 and 49.2 %,
respectively. Correspondingly, the 1-, 3-, and 5-year OS rates were 98.9, 85.1 and 77.4 % in the NLR ≤ 2.17 group
and 97.9, 63.8 and 53.3 % in the NLR > 2.17 group, respectively. The multivariate Cox proportional hazard model
analysis showed that NLR > 2.17 was a prognostic factor for both DFS [hazard ratio (HR) = 1.869; 95 % confidence
interval (CI) 1.078–3.243; P = 0.026] and OS (HR =2.177; 95 % CI 1.208–3.924; P = 0.010).
Conclusion: Our results showed that elevated preoperative NLR was an independent predictor of poor prognosis
for patients with LSCC after surgical resection.
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Background
Laryngeal squamous cell carcinoma (LSCC) is one of the
most common head and neck malignancies that remain as
significant cause of morbidity and mortality. Approxi-
mately 650,000 new cases and 350,000 cancer deaths
attributed to this condition occur every year [1, 2]. Treat-
ment options in LSCC include surgery, radiotherapy,
chemotherapy, or a combination of surgery, radio- and
chemotherapy [3–7]. Despite improvements in treatment,
an epidemiological survey indicated that the clinical out-
come for LSCC has improved little in the past 20 years
[8]. Therefore, it is of great significance to find novel and
effective biomarkers for prediction of LSCC patients with
poor prognosis or at high risk of early recurrence.
Recently, there is increasing evidence that the host
inflammatory response to cancer is associated with poor
tumor-specific prognosis. Kawata et al. reported that
lymphocyte infiltration around the tumor is associated
with a better prognosis of HCC [9], whereas neutrophil
in tumor stroma is associated with a poor prognosis [10].
Likewise, the neutrophil-to-lymphocyte ratio (NLR), a
predictor of the patient’s inflammatory status, has been
shown to be an effective prognostic marker in many solid
tumors [11–17]. Kum et al. showed that neutrophil-to-
lymphocyte ratio elevated in squamous cell carcinoma of
larynx compared to benign and precancerous laryngeal
lesions [18]. To our knowledge, the prognostic value of* Correspondence: szhang555@hotmail.com; chenshaohua1168@163.comDepartment of Otorhinolaryngology, Guangdong General Hospital &
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NLR in laryngeal squamous cell carcinoma has not been
reported.
In this study, we evaluated the prognostic value of pre-




Clinical data were collected from patients with LSCC
who underwent surgical resection at the Department of
Otorhinolaryngology, Guangdong General Hospital &
Guangdong Academy of Medical Sciences from January
2006 to August 2011. Clinical stage of laryngeal cancer
was determined according to the AJCC- TNM stage
(7th ed, 2010) [19]. The selective criteria for the patients
were as follows: (1) laryngeal squamous cell carcinoma
confirmed by pathology, (2) older than 18 years of age; (3)
complete clinical, laboratory, imaging, and follow-up data;
(4) no evidence of sepsis [11]; (5) no hematological disor-
ders or treatment that could result in an elevated NLR, for
example, administration of hematopoietic agents such as
granulocyte-colony stimulating factor (G-CSF) within
1 month before surgery; (6) no autoimmune disease or
treatment with steroids; (7) no pre-operative treatments
such as radiotherapy or chemotherapy; (8) patients were
treated with curative intent. Routine blood tests were
performed on the day before surgery. NLR was defined as
the absolute neutrophil count divided by the absolute
lymphocyte count. Patients were followed-up every
3 months for survival status, disease progression and time
of death. The last follow-up was 30 September 2014.
Disease-free survival (DFS) was recorded from the date of
surgery to the date of recurrence, or last follow-up.
Overall survival (OS) was recorded from the date of
surgery to the date of death or last follow-up. This study
was approved by the Research Ethics Committee of
Guangdong General Hospital & Guangdong Academy of
Medical Sciences. All participants signed informed con-
sent to participate in the study.
Statistical analysis
All statistical analyses were performed with SPSS version
19.0 software (Chicago, IL, USA). The chi-square test
was used to compare categorical variables. Survival
curves were plotted using the Kaplan-Meier method and
compared using the log-rank test. Factors analyzed by
univariate analysis with P < 0.05 were included in multiple




A total of 141 patients were eligible for the study. The
median age at diagnosis was 59 (range 36–87) years.
There were 137 men and 4 women. Eighty-three patients
(58.9 %, 83/141) had a smoking index of 20 pack-year or
more [20], and 24 patients (17.0 %, 24/141) had a drinking
index of 1000 g-year or more [21]. Surgical procedures
included total laryngectomy (43 cases, 30.5 %), partial
laryngectomy (64 cases, 45.4 %), and CO2 laser surgery
(34 cases, 24.1 %). The locations of tumors included
80.2 % (113/141) glottic, 17.0 % (24/141) supraglottic and
2.8 % (4/141) subglottic. Most of the patients were in the
N0 stage (83.7 %, 118/141), with 23 patients (16.3 %, 23/
141) in the N1 to N3 stages. Eighty-six patients (61.0 %,
86/141) were in T1 to T2 stages, and 55 patients (39.0 %,
55/141) were in the T3 to T4 stages. Details of features are
shown in Table 1.
Table 1 Correlation between peripheral NLR and
clinicopathologic variables of LSCC patients
NLR
Variables Cases NLR≤ 2.17 NLR > 2.17 P
Age (years)
≤ 60 74 48 (64.9 %) 26 (35.1 %)
> 60 67 46 (68.7 %) 21 (31.3 %) 0.633
Sex
Male 137 90 (65.7 %) 47 (34.3 %)
Female 4 4 (100.0 %) 0 0.151
Smoking history
Yes 83 54 (65.1 %) 29 (34.9 %)
No 58 40 (69.0 %) 18 (31.0 %) 0.628
Drinking history
Yes 24 15 (62.5 %) 9 (37.5 %)
No 117 79 (67.5 %) 38 (32.5 %) 0.635
T classification
T1–T2 86 62 (72.1 %) 24 (27.9 %)
T3–T4 55 32 (58.2 %) 23 (41.2 %) 0.087
Lymph node metastasis
Negative 118 80 (67.8 %) 38 (32.2 %)
Positive 23 14 (60.9 %) 9 (39.1 %) 0.519
Histological grade
Well 48 34 (70.8 %) 14 (29.2 %)
Moderately 73 48 (65.8 %) 25 (34.2 %)
Poorly 20 12 (60.0 %) 8 (40.0 %) 0.670
Primary location
Supraglottic 24 15 (62.5 %) 9 (37.5 %)
Glottic 113 77 (68.1 %) 36 (31.9 %) 0.671
Subglottic 4 2 (50.0 %) 2 (50.0 %)
Clinical stage
I–II 80 58 (72.5 %) 22 (27.5 %)
III–IV 61 36 (59.0 %) 25 (41.0 %) 0.092
NLR neutrophil-to-lymphocyte ratio, LSCC Laryngeal squamous cell carcinoma
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An optimal cutoff value for elevated NLR
To avoid a predetermined cutoff point, the optimal cutoff
score of preoperative NLR was defined by receiver operat-
ing characteristic (ROC) curve analysis. The cutoff value
was that point closest to both maximum sensitivity and
specificity. According to the ROC curve, the optimal cut-
off value of preoperative NLR was 2.17. The area under
the ROC curves was 0.614 with a 95 % confidence interval
(95 % CI) for the area between 0.515 and 0.713 (P = 0.024)
(Fig. 1). Clinicopathological features according to NLR
groups are summarized in Table 1.
DFS and OS according to NLR status
The 141 patients were divided into two groups: NLR ≤
2.17 and NLR > 2.17. The median patients’ follow-up was
51 months (range: 5–102 months; mean ± SD: 54.1 ±
23.4 months). Ninety-six patients were alive at the end of
follow-up and 52 patients developed recurrence 5–102
months after surgery (median 46 months). In the NLR ≤
2.17 group, the 1-, 3-, and 5-year DFS rates were 88.2,
73.9 and 69.1 %, respectively, while in the NLR > 2.17
group, the DFS rates were 83.0, 54.6 and 49.2 %, respect-
ively (Fig. 2). Correspondingly, the 1-, 3-, and 5-year OS
rates were 98.9, 85.1 and 77.4 % in the NLR ≤ 2.17 group
and 97.9, 63.8 and 53.3 % in the NLR > 2.17 group,
respectively (Fig. 3). Both DFS and OS of patients in the
NLR ≤ 2.17 group were significantly longer than for
patients in the NLR > 2.17 group.
Risk factors for prognosis of LSCC
For all patients included in this study, the 1-, 3- and 5-year
DFS rates were 86.5, 67.5 and 62.4 %, respectively. Rates for
OS at the 1-, 3- and 5-year period were 98.6, 78.0 and
69.4 %, respectively. Univariate analysis revealed that
advanced T classification (T3 and T4 stages), Lymph node
metastasis, primary location, NLR > 2.17 and advanced
clinic stage were associated with significantly poor DFS.
Similarly, advanced Tclassification, Lymph node metastasis,
primary location, NLR > 2.17, poor histological grade and
advanced clinical stage all predicted poor OS (Table 2).
Clinical stage was first excluded from the multivariable
analyses because it was a comprehensive variable, and the
other variables were entered stepwise into the multivariable
Cox proportional hazard model by the forward conditional
method. The analysis showed that NLR > 2.17 (HR = 1.869;
95 % CI 1.078–3.243; P = 0.026) and lymph node metastasis
(HR = 3.224; 95 % CI 1.751–5.937; P < 0.001) were inde-
pendent prognostic factors for DFS in patients with LSCC.
NLR > 2.17 (HR = 2.177; 95 % CI 1.208–3.924; P = 0.010),
lymph node metastasis (HR = 2.968; 95 % CI 1.548–5.692;
P = 0.001) and advanced T classification (HR = 1.867; 95 %
CI 1.018–3.425; P = 0.044) were independent prognostic
factors for OS in patients with LSCC (Table 3).
Fig. 1 Receiver operating characteristic curves of preoperative neutrophil-to-lymphocyte ratio (NLR) for predicting tumor recurrence in patients
with Laryngeal squamous cell carcinoma (LSCC) after surgical resection
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Fig. 2 Kaplan-Meier survival curves for DFS in patients with LSCC after surgical resection. Disease-free survival of patients with NLR > 2.17 was shorter
than those with NLR≤ 2.17 (P = 0.021, log-rank)
Fig. 3 Kaplan-Meier survival curves for OS in patients with LSCC after surgical resection. Overall survival of patients with NLR > 2.17 was also shorter
than those with NLR≤ 2.17 (P = 0.003, log-rank)
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Discussion
Recent evidence suggests that the development and pro-
gression of cancers is closely associated with inflamma-
tion and immunity status. The neutrophil-to-lymphocyte
ratio is a simple and effective marker of inflammation
and immunity. It reflects the patient’s inflammatory and
immunity status. NLR has been shown to be a valuable
prognostic marker in patients with some solid tumors in
many studies, such as hepatocellular carcinoma [11, 22],
gastric cancer [23], soft tissue sarcoma [24], esophageal
cancer [17, 25] and breast cancer [26, 27]. However, the
cutoff value of NLR is not consistent. In most studies,
Table 2 Prognostic factors for DFS and OS by univariate analysis
Variables n DFS OS
3-years 5-years P 3-years 5-years P
Age (years)
≤ 60 74 65.6 % 64.1 % 75.7 % 72.7 %
> 60 67 69.4 % 60.7 % 0.980 80.6 % 66.9 % 0.41
Smoking history
Yes 83 68.3 % 62.7 % 74.7 % 67.2 %
No 58 66.3 % 62.2 % 0.886 82.8 % 73.0 % 0.464
Drinking history
Yes 24 66.4 % 61.7 % 66.7 % 61.1 %
No 117 67.7 % 62.6 % 0.845 80.3 % 71.1 % 0.414
T classification
T1–T2 86 74.3 % 68.6 % 87.2 % 79.6 %
T3–T4 55 56.1 % 51.8 % 0.039 63.6 % 53.7 % 0.003
Lymph node metastasis
Negative 118 73.3 % 68.4 % 83.9 % 75.9 %
Positive 23 35.5 % 28.4 % <0.001 47.8 % 35.9 % <0.001
NLR
≤ 2.17 94 73.9 % 69.1 % 85.1 % 77.4 %
> 2.17 47 54.6 % 49.2 % 0.021 63.8 % 53.3 % 0.003
Histological grade
Well 48 83.0 % 70.5 % 93.7 % 80.4 %
Moderately 73 59.6 % 59.6 % 74.0 % 67.4 %
Poorly 20 59.6 % 53.6 % 0.169 55.0 % 49.5 % 0.043
Primary location
Supraglottic 24 55.9 % 43.1 % 58.3 % 37.4 %
Glottic 113 69.5 % 66.6 % 82.3 % 77.4 %
Subglottic 4 75.0 % 50.0 % 0.165 75.0 % 50.0 % 0.001
Clinical stage
I–II 80 74.9 % 70.3 % 87.5 % 81.1 %
III–IV 61 57.2 % 51.4 % 0.022 65.6 % 54.5 % 0.004
DFS disease-free survival, OS overall survival. Other abbreviations are the same as in Table 1
Table 3 Prognostic factors for DFS and OS as determined by multivariate Cox proportional hazards regression model
Variables DFS OS
HR 95 % CI P HR 95 % CI P
T classification 1.867 1.018–3.425 0.044
Lymph node metastasis 3.224 1.751–5.937 <0.001 2.968 1.548–5.692 0.001
NLR 1.869 1.078–3.243 0.026 2.177 1.208–3.924 0.010
HR hazard ratio, CI confidence interval. Other abbreviations are the same as in Tables 1 and 2
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the cutoff value of NLR has been empirically set. To
avoid a predetermined cutoff point, we determined that
the optimal cutoff value of NLR was 2.17 for predicting
prognosis of patients with LSCC by using ROC curve
analysis in this study. To the best of our knowledge, this
study is the first to evaluate the prognostic role of NLR
in patients with LSCC.
We found that patients with elevated NLR (>2.17) had
significantly shorter DFS and OS than those with low NLR
(≤2.17) (Figs. 2 and 3, Table 2). The multiple Cox propor-
tional hazard regression analysis showed that NLR > 2.17
was an independent prognostic factor of short DFS and
OS in patients with LSCC. The relationship between a
high pretreatment NLR and poor prognosis has also been
observed in patients with other squamous cell carcinoma
[17, 25, 28, 29]. Recently, Kum et al. demonstrated that
NLR was a useful inflammatory marker to differentiate
LSCC patients from benign laryngeal lesion (BLL) and
precancerous laryngeal lesion (PLL) patients [18].
Although the association between elevated NLR and
poor prognosis has been confirmed by many studies, the
underlying mechanisms have not yet been fully elucidated
[11–16]. One possible explanation is that a relatively in-
creased number of circulating neutrophils produced and
secreted angiogenesis-regulating growth factors, chemo-
kines and proteases (e.g., vascular endothelial growth factor
(VEGF) [30], interleukin-8 (IL-8) [31], intercellular adhe-
sion molecule 1 [32] and matrix metalloproteinase (MMP))
[33] which may promote tumor growth and metastasis
resulting in poor prognosis. Another explanation is that the
host immune response to tumors is lymphocyte dependent.
Patients with elevated NLR usually have relative lymphocy-
topenia, and this may reflect a deficient immune response
to tumors mediated by CD4+ T-helper and cytotoxic CD8+
cell [34].
Conclusions
This study demonstrated that elevated preoperative NLR
was an independent prognostic marker of poor DFS and
OS in patients with LSCC. NLR is a simple, easily accessible
indicator for identifying LSCC patients following surgical
resection. It might help clinicians support intensive follow-
up surveillance and adopt personalized adjuvant therapies
for patients with LSCC who were at high risk for recur-
rence after surgical resection. It is noted that this study is
limited by its retrospective nature and the relatively small
size in a single-center. Further multicenter, large prospect-
ive studies are needed to confirm the findings.
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